Pro-Drug Conjugates

The pro-drug polymer conjugation approach can optimize the pharmacokinetics and pharmacodynamics of a drug to substantially increase both its efficacy and side effect profile. Nektar is currently using this platform with oncolytics, which typically have sub-optimal half-lives which can limit their therapeutic efficacy. With Nektar's platform, these drugs can be modulated to optimize bioactivity and increase the sustained exposure of active drug to tumor cells in the body.

Nektar is using this approach with the two lead oncology candidates in our pipeline, NKTR-102 and NKTR-105.

Read more about NKTR-105 »

With a pro-drug design, several drug molecules are attached to a large molecular weight polymer in a multi- arm architecture. The drug molecules are conjugated with programmable releasable linkers. The linkers themselves can be customized to achieve the target product pharmacokinetic profile by controlling the rate of release. The active parent molecule is then cleaved from the prodrug through pH or enzymatic hydrolysis. The linkers release the drug, either sequentially or simultaneously, to achieve the desired target pharmacokinetics profile needed to maximize therapeutic efficacy.

Large Molecule Polymer Conjugates »

Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide